Translocation of Methionine Adenosyl Transferase MAT2A and Its Prognostic Relevance for Liver Hepatocellular Carcinoma

• Published in: International journal of molecular sciences Vol. 24; no. 10; p. 9103
• Main Authors: Chu, Pei-Yi, Chou, Dev-Aur, Chen, Po-Ming, Chiang, En-Pei Isabel
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22.05.2023; MDPI
• Subjects: Amino acids; Analysis; Breast cancer; Cancer; Cancer patients; Carcinoma, Hepatocellular - metabolism; Cell growth; Development and progression; DNA methylation; Enzymes; Estrogen; Female; Gene expression; Genes; Genetic aspects; Health aspects; Hepatoma; Humans; Investigations; Liver; Liver cancer; Liver diseases; Liver Neoplasms - metabolism; Localization; Male; Medical prognosis; Methionine Adenosyltransferase - metabolism; Oncology, Experimental; Prognosis; Protein expression; Proteins; RNA; S-Adenosylmethionine - metabolism; Transferases; Women; Taiwan; LIHC; MAT1A; MAT2A; subcellular localization; prognosis; GNMT
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24109103

Methionine adenosyl transferases (MATs) catalyze the synthesis of the biological methyl donor adenosylmethionine (SAM). Dysregulation of MATs has been associated with carcinogenesis in humans. We previously found that downregulation of the MAT1A gene enriches the protein-associated translation process and worsens liver hepatocellular carcinoma (LIHC) prognosis. We also discovered that subcellular localization of the MAT2A protein has independently prognostic relevance in breast cancer patients. The present study aimed to examined the clinical relevance of MAT2A translocation in human LIHC. Essential methionine cycle gene expressions in TCGA LIHC datasets were analyzed using Gene Expression Profiling Interactive Analysis 2 (GEPIA2). The protein expression pattern of MAT2A was determined in the tissue array of our own LIHC cohort (n = 261) using immuno-histochemistry, and the prognostic relevance of MAT2A protein’s subcellular localization expression was examined using Kaplan–Meier survival curves. LIHC patients with higher MAT2A mRNA expression had a worse survival rate (p = 0.0083). MAT2A protein immunoreactivity was observed in both cytoplasm and nucleus fractions in the tissue array. Tumor tissues had elevated MAT2A protein expression in both cytoplasm and nucleus compared to their adjacent normal tissues. A higher cytoplasmic to nuclear MAT2A protein expression ratio (C/N) was found in female LIHC patients compared to that of male patients (p = 0.047). Kaplan–Meier survival curves showed that a lower MAT2A C/N correlated with poor overall survival in female LIHC patients (10-year survival rate: 29.2% vs. 68.8%, C/N ≤ 1.0 vs. C/N > 1.0, log-rank p = 0.004). Moreover, we found that specificity protein 1 (SP1) may have a potential interaction with nuclear MAT2A protein, using protein–protein interaction; this we found using the GeneMANIA algorithm. We explored the possible protective effects of the estrogen axis in LIHC using the Human Protein Atlas (HPA), and found evidence supporting a possible protective effect of estrogen-related protein ESSRG in LIHC. The localization of SP1 and MAT2 appeared to be inversely associated with ESRRG expression in LIHC. The present study demonstrated the translocation of MAT2A and its prognostic relevance in female LIHC patients. Our findings suggest the potential of estrogen in SP1 regulation and localization of MAT2A, as therapeutic modalities against in female LIHC patients.